SG171635A1 - Therapeutic piperazines as pde4 inhibitors - Google Patents
Therapeutic piperazines as pde4 inhibitorsInfo
- Publication number
- SG171635A1 SG171635A1 SG201103040-0A SG2011030400A SG171635A1 SG 171635 A1 SG171635 A1 SG 171635A1 SG 2011030400 A SG2011030400 A SG 2011030400A SG 171635 A1 SG171635 A1 SG 171635A1
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic
- piperazines
- compounds
- pde4 inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77729106P | 2006-02-28 | 2006-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG171635A1 true SG171635A1 (en) | 2011-06-29 |
Family
ID=38279005
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201103039-2A SG171634A1 (en) | 2006-02-28 | 2007-02-27 | Therapeutic piperazines as pde4 inhibitors |
SG201103040-0A SG171635A1 (en) | 2006-02-28 | 2007-02-27 | Therapeutic piperazines as pde4 inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201103039-2A SG171634A1 (en) | 2006-02-28 | 2007-02-27 | Therapeutic piperazines as pde4 inhibitors |
Country Status (15)
Country | Link |
---|---|
US (4) | US7829713B2 (pt) |
EP (2) | EP2562168B1 (pt) |
JP (1) | JP2009528363A (pt) |
CN (1) | CN101490017B (pt) |
AR (1) | AR059686A1 (pt) |
AU (1) | AU2007221021B2 (pt) |
BR (1) | BRPI0708337A2 (pt) |
CA (1) | CA2644069A1 (pt) |
ES (1) | ES2462240T3 (pt) |
HK (1) | HK1185063A1 (pt) |
IL (1) | IL193674A0 (pt) |
NZ (1) | NZ570844A (pt) |
SG (2) | SG171634A1 (pt) |
TW (1) | TW200804309A (pt) |
WO (1) | WO2007100852A1 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2562168B1 (en) * | 2006-02-28 | 2014-04-16 | Dart Neuroscience (Cayman) Ltd | Therapeutic piperazines as pde4 inhibitors |
US8927546B2 (en) * | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
CA2680414A1 (en) * | 2007-03-12 | 2008-09-18 | Biolipox Ab | Piperidinones useful in the treatment of inflammation |
GB0722769D0 (en) * | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
MY148657A (en) | 2007-04-27 | 2013-05-15 | Purdue Pharma Lp | Trpv1 antagonists and uses thereof |
UY32858A (es) * | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
AU2010346633B2 (en) * | 2010-02-24 | 2015-12-03 | Research Triangle Institute | Arylpiperazine opioid receptor antagonists |
WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
MY185061A (en) | 2011-06-22 | 2021-04-30 | Shionogi & Co | Trpv1 antagonists including dihydroxy substituent and uses thereof |
WO2014017643A1 (ja) | 2012-07-27 | 2014-01-30 | 佐藤製薬株式会社 | ジフルオロメチレン化合物 |
CA2894130A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
JP6678455B2 (ja) | 2012-12-21 | 2020-04-08 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
CN108299400B (zh) | 2013-03-14 | 2021-02-19 | 达特神经科学(开曼)有限公司 | 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物 |
EP3177288A4 (en) | 2014-08-04 | 2018-04-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
JP2022553802A (ja) | 2019-10-31 | 2022-12-26 | エスケープ・バイオ・インコーポレイテッド | S1p受容体モジュレーターの固体形態 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2996507A (en) * | 1959-09-09 | 1961-08-15 | Abbott Lab | Piperazine compounds |
US3306903A (en) * | 1965-10-07 | 1967-02-28 | Council Scient Ind Res | 1-aminopyridyl-4-(phenyl or pyridyl)-piperazines and intermediates |
FR2262964B1 (pt) * | 1973-04-05 | 1978-07-28 | Synthelabo | |
AT330777B (de) * | 1973-09-08 | 1976-07-26 | Thomae Gmbh Dr K | Verfahren zur herstellung von neuen isochinolinderivaten und deren salzen |
DE2345422C2 (de) * | 1973-09-08 | 1983-12-22 | Dr. Karl Thomae Gmbh, 7950 Biberach | Substituierte Isochinolyl-arylpiperazine diese enthaltende Arzneimittel sowie Verfahren zu deren Herstellung |
GB1575904A (en) * | 1976-04-23 | 1980-10-01 | Lilly Industries Ltd | Phenyl piperazines |
US4093726A (en) * | 1976-12-02 | 1978-06-06 | Abbott Laboratories | N-(2-benzimidazolyl)-piperazines |
US4666911A (en) * | 1981-07-14 | 1987-05-19 | Taiho Pharmaceutical Company Limited | Allophanoylpiperazine compound and analgesic composition containing same as active ingredient |
FR2533212A1 (fr) * | 1982-09-22 | 1984-03-23 | Lipha | Benzo-et thieno-triazine-1,2,3 ones-4 procedes de preparation et medicaments les contenant |
FR2551753B2 (fr) * | 1982-09-22 | 1986-02-28 | Lipha | Benzotriazine-1,2,3-ones-4, procede de preparation et medicaments les contenant |
DE3442860A1 (de) * | 1984-11-24 | 1986-05-28 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 5-alkyl-1-phenyl-2-piperazinoalkylpyrazolin-3- on-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
ATE81975T1 (de) * | 1984-12-21 | 1992-11-15 | Duphar Int Res | Arzneimittel mit psychotroper wirkung. |
US4845100A (en) | 1985-04-12 | 1989-07-04 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same |
IT1187751B (it) * | 1985-10-15 | 1987-12-23 | Eurand Spa | Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute |
US4960776A (en) | 1987-01-28 | 1990-10-02 | A. H. Robins Company, Inc. | 4-aryl-N-(alkylaminoalkyl, heterocyclicamino and heterocyclicamino)alkyl)-1-piperazinecarboxamides |
US5204482A (en) | 1988-07-28 | 1993-04-20 | Hoffman-Laroche Inc. | Compounds for treating and preventing cognitive diseases and depression and methods of making same |
US5086055A (en) * | 1990-12-24 | 1992-02-04 | A. H. Robins Company, Incorporated | Series of 5-[-(4-aryl-1-piperazinyl)alkyl]-2-oxazolidinone derivatives useful in the treatment of allergic conditions |
CA2067663A1 (en) * | 1991-05-01 | 1992-11-02 | Hitoshi Tone | Pyrazine derivatives |
FR2680172B1 (fr) | 1991-08-05 | 1993-11-19 | Fabre Medicament Pierre | Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique. |
DE4241563A1 (de) * | 1992-12-10 | 1994-06-16 | Basf Ag | Neue Triazolochinazoline, ihre Herstellung und Verwendung |
JPH10152470A (ja) * | 1996-09-25 | 1998-06-09 | Yoshitomi Pharmaceut Ind Ltd | ピペラジン化合物 |
DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
ID23921A (id) | 1997-11-04 | 2000-05-25 | Pfizer Prod Inc | Penggantian indazola bioisostere katekol pada senyawa-senyawa aktif untuk terapi |
AR025884A1 (es) | 1999-10-01 | 2002-12-18 | Takeda Pharmaceutical | Compuestos de amina ciclica, su produccion y su uso |
EP2258689A1 (en) * | 2000-03-16 | 2010-12-08 | Biolipox AB | Benzylated PDE4 inhibitors |
US8153646B2 (en) * | 2000-08-10 | 2012-04-10 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
EP1389189A2 (en) * | 2001-05-22 | 2004-02-18 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
AU2002326948A1 (en) | 2001-09-18 | 2003-04-01 | Bristol-Myers Squibb Company | Piperizinones as modulators of chemokine receptor activity |
US7589199B2 (en) * | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
JP2005539001A (ja) | 2002-08-02 | 2005-12-22 | アージェンタ・ディスカバリー・リミテッド | ヒストンデアセチラーゼインヒビターとしての置換チエニルヒドロキサム酸 |
EP1529049B1 (en) | 2002-08-08 | 2009-11-18 | Memory Pharmaceuticals Corporation | Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
BR0314392A (pt) | 2002-09-16 | 2005-07-12 | Glaxo Group Ltd | Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação |
SE0300010D0 (sv) | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
EP1599447A1 (en) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
DE10315571A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Pyrazolverbindungen |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
GB0322510D0 (en) * | 2003-09-25 | 2003-10-29 | Glaxo Group Ltd | Novel compounds |
US20050250789A1 (en) * | 2004-04-20 | 2005-11-10 | Burns David M | Hydroxamic acid derivatives as metalloprotease inhibitors |
WO2006078287A2 (en) | 2004-05-06 | 2006-07-27 | Plexxikon, Inc. | Pde4b inhibitors and uses therefor |
US7429666B2 (en) * | 2004-06-10 | 2008-09-30 | Merck Frosst Canada Ltd. | Pyridine analogs as C5a antagonists |
US20090093485A1 (en) | 2004-10-29 | 2009-04-09 | Astrazeneca Ab | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases |
GT200600042A (es) * | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
WO2007002563A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Imidazole based lxr modulators |
EP1931658A2 (en) | 2005-09-07 | 2008-06-18 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
EP2562168B1 (en) * | 2006-02-28 | 2014-04-16 | Dart Neuroscience (Cayman) Ltd | Therapeutic piperazines as pde4 inhibitors |
US8927546B2 (en) * | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
MX2007012313A (es) * | 2006-04-19 | 2007-11-21 | Boehringer Ingelheim Int | Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias. |
CA2722582A1 (en) | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf. | Biaryl pde4 inhibitors for treating inflammation |
-
2007
- 2007-02-27 EP EP12160350.0A patent/EP2562168B1/en not_active Not-in-force
- 2007-02-27 NZ NZ570844A patent/NZ570844A/en not_active IP Right Cessation
- 2007-02-27 US US11/679,782 patent/US7829713B2/en not_active Expired - Fee Related
- 2007-02-27 SG SG201103039-2A patent/SG171634A1/en unknown
- 2007-02-27 WO PCT/US2007/005159 patent/WO2007100852A1/en active Application Filing
- 2007-02-27 BR BRPI0708337-8A patent/BRPI0708337A2/pt not_active IP Right Cessation
- 2007-02-27 JP JP2008557345A patent/JP2009528363A/ja active Pending
- 2007-02-27 ES ES12160350.0T patent/ES2462240T3/es active Active
- 2007-02-27 CN CN2007800143821A patent/CN101490017B/zh not_active Expired - Fee Related
- 2007-02-27 CA CA002644069A patent/CA2644069A1/en not_active Abandoned
- 2007-02-27 SG SG201103040-0A patent/SG171635A1/en unknown
- 2007-02-27 TW TW096106660A patent/TW200804309A/zh unknown
- 2007-02-27 EP EP07751890.0A patent/EP1989188B1/en not_active Not-in-force
- 2007-02-27 AU AU2007221021A patent/AU2007221021B2/en not_active Ceased
- 2007-02-28 AR ARP070100831A patent/AR059686A1/es unknown
-
2008
- 2008-08-25 IL IL193674A patent/IL193674A0/en unknown
-
2010
- 2010-08-23 US US12/861,213 patent/US8338405B2/en active Active
- 2010-09-01 US US12/873,452 patent/US8501745B2/en not_active Expired - Fee Related
-
2013
- 2013-07-31 US US13/955,037 patent/US20140038945A1/en not_active Abandoned
- 2013-08-27 HK HK13110046.8A patent/HK1185063A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SG171634A1 (en) | 2011-06-29 |
TW200804309A (en) | 2008-01-16 |
EP2562168A1 (en) | 2013-02-27 |
NZ570844A (en) | 2011-11-25 |
US8338405B2 (en) | 2012-12-25 |
CA2644069A1 (en) | 2007-09-07 |
US20110065689A1 (en) | 2011-03-17 |
CN101490017A (zh) | 2009-07-22 |
AU2007221021B2 (en) | 2013-01-17 |
US8501745B2 (en) | 2013-08-06 |
CN101490017B (zh) | 2013-01-23 |
AU2007221021A1 (en) | 2007-09-07 |
IL193674A0 (en) | 2009-05-04 |
US20070203124A1 (en) | 2007-08-30 |
AR059686A1 (es) | 2008-04-23 |
WO2007100852A1 (en) | 2007-09-07 |
HK1185063A1 (en) | 2014-02-07 |
EP1989188A1 (en) | 2008-11-12 |
ES2462240T3 (es) | 2014-05-22 |
EP1989188B1 (en) | 2015-07-22 |
US20110065688A1 (en) | 2011-03-17 |
US7829713B2 (en) | 2010-11-09 |
US20140038945A1 (en) | 2014-02-06 |
EP2562168B1 (en) | 2014-04-16 |
BRPI0708337A2 (pt) | 2011-05-24 |
JP2009528363A (ja) | 2009-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG171635A1 (en) | Therapeutic piperazines as pde4 inhibitors | |
TW200610531A (en) | Phthalazine derivatives as PARP inhibitors | |
JO2962B1 (en) | Aminopronic derivatives substituted as niprilicin inhibitors | |
HK1154002A1 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
MX2009000884A (es) | Derivados de piridizinona. | |
TW200744586A (en) | Therapeutic compounds | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
UA94833C2 (en) | Substituted bicyclolactams | |
EP2613782A4 (en) | INDAZOLE DERIVATIVES AS INHIBITORS OF THE ERK PATHWAY | |
WO2008107478A8 (en) | Quinolinone derivatives as parp and tank inhibitors | |
UA85593C2 (uk) | Похідні хіназолінону як інгібітори parp | |
MX344669B (es) | Agente antiplaquetas novedoso. | |
SG154432A1 (en) | Quinazolinedione derivatives as parp inhibitors | |
MA34064B1 (fr) | Compose heterocyclique | |
TN2012000129A1 (en) | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | |
WO2007148185A3 (en) | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors | |
TNSN08191A1 (en) | Kinase inhibitors | |
TW200745084A (en) | Novel compounds | |
EA200900135A1 (ru) | Производные пиразола в качестве ингибиторов цитохрома р450 | |
SE0400284D0 (sv) | Novel compounds | |
EA201270590A1 (ru) | Ингибиторы акт | |
UA96759C2 (en) | 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS | |
TW200738627A (en) | Trialkylsilyl-indoles | |
WO2009105969A8 (zh) | 埃坡霉素类似物、其药物组合物、用途及其制备方法 | |
MX2010001303A (es) | Compuestos terapeuticos. |